Rapid Drug Sensitivity Profiling via a Novel High-Success-Rate Culture Method for Patient-Derived Pancreatic Cancer: An Exploratory Preclinical Platform for Advancing Clinical Applications and Drug Development.

Pancreatic cancer is a highly intractable malignancy that necessitates personalized treatment strategies. Conventional patient-derived models, such as three-dimensional organoids, are often limited by intellectual property constraints and high costs. In this study, we developed an affordable adherent culture system for patient-derived pancreatic cancer cells using a proprietary medium and laminin-coated dishes. Primary cultures were successfully established from 28 patients with pancreatic ductal adenocarcinoma, exceeding a 90% success rate. Validation of eight samples confirmed maintenance of epithelial cell adhesion molecule expression and preservation of oncogenic mutations. Transcriptomic profiling revealed consistent upregulation of a six-gene signature (, , , , , and ), which is associated with malignancy. In vitro drug sensitivity assays revealed interpatient heterogeneity with preliminary clinical associations. In conclusion, this simplified platform provides high-purity cancer cells and serves as a functional precision medicine tool. Beyond conventional chemotherapy, this platform has the potential to support applications ranging from biomarker validation and exploratory preclinical testing of novel therapeutics, including immune checkpoint inhibitors and antibody-drug conjugates. This optimization can lead to personalized therapeutic strategies for pancreatic cancer.